Eurogentec and Applied Biosystems Sign Dual-Labeled Probe Manufacturing License Agreement
News Nov 04, 2009
Eurogentec S.A. has announced that it has obtained a license from Applied Biosystems', part of Life Technologies Corporation, (AB) under AB's Probe Manufacturing License Program.
Under the agreement, Eurogentec and its affiliates are licensed to manufacture and sell dual-labeled oligonucleotide probes worldwide for use in the 5' Nuclease process. This process is one of the key technologies driving real-time polymerase chain reaction (PCR) assays.
Enhancing the expanded PCR License Agreement previously signed with AB, the Probe Manufacturing Agreement conveys a license to Eurogentec to custom manufacture, market and sell dual-labeled probes alone as well as in complete kits. These kits may contain dual-labeled probes, primers and reagents packaged and sold with other components. The agreement grants limited pass through 'Use' rights to Eurogentec's research customers.
The agreement also conveys rights under several probe composition and methods patents (including U.S. Patent No. 5,804,375, the '375' patent) to offer oligonucleotide design services for probes and primers for use in real-time PCR.
"Eurogentec is pleased to become one of the first oligonucleotide manufacturers to be licensed under AB's Probe Manufacturing License Program," commented Dr. Philippe Cronet, Chief Scientific Officer at Eurogentec.
The addition of licensed, custom-synthesized dual-labeled probes is an important enhancement to the comprehensive catalog of PCR products and services already available to our customers. Moreover, the new agreement confirms the validity of our previous investments in PCR and real-time PCR.
In addition to the benefits for the research market, the new agreement is an important cornerstone in our on-going commitment to serve the commercial molecular diagnostic assay market. Assay kit manufacturers and other entities holding a 5'-Nuclease commercial use license may purchase ISO 13485 and GMP/QSR compliant probes, primers and kits that are custom-manufactured by Eurogentec.
Dr. Cronet concluded that "enhancing its already prominent position in the European life science market, Eurogentec's increased presence in the North American and Asian life science research and diagnostic markets and the rights conveyed by AB to provide licensed dual-labeled probes, ideally positions the company to provide scientists world-wide with the high-performance PCR products and complete PCR solutions they require."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.